Lantheus Holdings (LNTH) Other Non-Current Liabilities (2014 - 2026)
Lantheus Holdings' (LNTH) quarterly Other Non-Current Liabilities came in at $49.9 million in Q1 2026, up 166.22% year-on-year from $18.7 million in Q1 2025, and down 53.75% on a QoQ basis from $107.9 million in Q4 2025.
Lantheus Holdings (LNTH) Other Non-Current Liabilities (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has 13 years of Other Non-Current Liabilities data on file, last reported at $49.9 million in Q1 2026.
- On a quarterly basis, Other Non-Current Liabilities rose 166.22% year-over-year to $49.9 million in Q1 2026; TTM through Mar 2026 was $49.9 million, a 166.22% increase from a year earlier, with the FY2025 full-year figure at $107.9 million, up 979.2% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $49.9 million, down from $107.9 million in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for LNTH reached as high as $107.9 million in Q4 2025 and fell as low as $136000.0 in Q2 2025.
- Historically, Other Non-Current Liabilities has averaged $32.3 million across 5 years, with a median of $22.9 million in 2023.
- On a YoY basis, Other Non-Current Liabilities climbed as much as 979.2% in 2025 and fell as far as 99.46% in 2025.
- Year by year, Other Non-Current Liabilities stood at $22.5 million in 2022, then climbed by 1.65% to $22.9 million in 2023, then sank by 56.38% to $10.0 million in 2024, then soared by 979.2% to $107.9 million in 2025, then plunged by 53.75% to $49.9 million in 2026.
- Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $49.9 million in Q1 2026, $107.9 million in Q4 2025, and $137000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Lantheus Holdings | 6.72 Bn | 6.22 Bn | 230.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49.89 Mn |
| Dec 31, 2025 | 107.87 Mn |
| Sep 30, 2025 | 137,000.00 |
| Jun 30, 2025 | 136,000.00 |
| Mar 31, 2025 | 18.74 Mn |
| Dec 31, 2024 | 10.00 Mn |
| Sep 30, 2024 | 23.24 Mn |
| Jun 30, 2024 | 25.10 Mn |
| Mar 31, 2024 | 63.11 Mn |
| Dec 31, 2023 | 22.92 Mn |
| Sep 30, 2023 | 62.85 Mn |
| Jun 30, 2023 | 3.00 Mn |
| Mar 31, 2023 | 22.64 Mn |
| Dec 31, 2022 | 22.54 Mn |
| Sep 30, 2022 | 46.49 Mn |
| Jun 30, 2022 | 49.62 Mn |
| Mar 31, 2022 | 21.51 Mn |
| Dec 31, 2021 | 20.83 Mn |
| Sep 30, 2021 | 89.64 Mn |
| Jun 30, 2021 | 91.79 Mn |